Exercise and Treatment-as-usual in Substance Use Treatment Outcomes

December 13, 2019 updated by: University of Wisconsin, Madison

Comparative Effects of Exercise and Treatment-as-usual on Abstinence, Craving, and the Endocannabinoid System in Substance Users

The research study compares the substance abuse treatment outcomes (e.g., craving, withdrawal symptoms, rates of use, abstinence) of standard intensive outpatient care, with or without an added 6-wk aerobic exercise component. In addition, certain biomarkers associated with both exercise and substance use (e.g., endocannabinoids and cortisol) will be assessed. In a rolling admissions format over the course of a year, approximately 36 treatment-seeking substance users who are currently receiving Intensive Outpatient Treatment through a local Alcohol or Other Drug Abuse agency will be randomized to either receive 6 weeks aerobic exercise training in addition to standard care or standard care with 6 weekly laboratory visits to complete questionnaires (18 per group).

Study Overview

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53706
        • University of Wisconsin-Madison

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Intact cognitive status and ability to provide informed consent
  • ability to read and write in English sufficient to provide consent and complete study questionnaires
  • current diagnosis of a single or of multiple substance use disorders
  • currently enrolled in an Intensive Outpatient Treatment substance use program
  • desire to quit and to seek treatment for substance use
  • currently sedentary, not participating in any formal/structured exercise program

Exclusion Criteria:

  • a history or present diagnosis of severe depression, psychotic, or bipolar disorder
  • presence of cardiac disease or any other medical condition that would make engaging in exercise unsafe
  • Undergoing methadone treatment
  • chronic conditions such as cancer, diabetes, kidney disease, or autoimmune disorders
  • women who are pregnant or planning to become pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: exercise
Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
Placebo Comparator: treatment-as-usual
Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Withdrawal Checklist: Change in physical and psychological withdrawal symptoms over the course of the intervention
Time Frame: up to 6 weeks
withdrawal symptoms will be assessed using the Withdrawal Checklist which asks participants to rate the severity of a variety physical and psychological symptoms over the past 48 hours. The total score on the Withdrawal Checklist will be used to provide an overall measured of withdrawal.
up to 6 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
change in cortisol concentrations
Time Frame: measured before and after sessions (via saliva swab) during the first, third, and sixth weeks of the 6-week intervention
measured before and after sessions (via saliva swab) during the first, third, and sixth weeks of the 6-week intervention
change in endocannabinoid concentrations
Time Frame: measured before and after sessions (via single venipuncture)during the first, third, and sixth weeks of the 6-week intervention
measured before and after sessions (via single venipuncture)during the first, third, and sixth weeks of the 6-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Angelique Brellenthin, MS, UW-Madison

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Actual)

September 1, 2016

Study Completion (Actual)

September 1, 2016

Study Registration Dates

First Submitted

September 29, 2015

First Submitted That Met QC Criteria

October 6, 2015

First Posted (Estimate)

October 7, 2015

Study Record Updates

Last Update Posted (Actual)

December 18, 2019

Last Update Submitted That Met QC Criteria

December 13, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 2015-0710
  • A176000 (Other Identifier: UW Madison)
  • EDUC\KINESIOLOGY\KINESIO (Other Identifier: UW Madison)
  • 1R36DA040140-01 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance-Related Disorders

Clinical Trials on exercise

Subscribe